The efficacy of tumor necrosis factor-alpha (TNF-\(\alpha\)) blockers is well established in patients with rheumatoid arthritis (RA).\(^1\) However, some published studies have reported a higher risk of surgical site of infection in the presence of TNF-\(\alpha\) blocker usage.\(^2,3\) These surgical site infections commonly occurred within four weeks of surgery. Later occurring infections were considered to be rare.\(^4\) In this article, we report rare acute onset of late infection after total hip arthroplasty (THA), following TNF-\(\alpha\) blocker therapy in two RA patients.

**CASE REPORT**

**Case 1**—A 74-year-old female with RA (Steinbrocker classification: functional class III, stage of disease progression 4) who was first diagnosed in 1973 was treated with non-biological disease-modifying antirheumatic drugs. The patient underwent left THA in 2009. Methotrexate therapy was started in 2010. However, methotrexate therapy caused rash in 2012. Therefore, we stopped methotrexate therapy, and changed the treatment with biological drug. Etanercept (25 mg/week) with steroids (5 mg/day) therapy was started in 2012. Two months later, patient presented again with complaints of left hip pain accompanied by elevated levels of inflammation markers [C-reactive protein (CRP), 26.2 mg/L (normal value; 0-0.3); white blood cells, 14,100 cell/mm\(^3\) (normal value; 3,500-9,000)]. Magnetic resonance imaging showed high intensity signal from left hip joint to subcutaneous tissue (Figure 1a, b). Aspiration fluid was pus, and *Escherichia coli* was detected in culture of joint aspiration. Thus the diagnosis of deep joint infection was confirmed. Open
debridement with retention of the prosthesis was performed immediately. Cephalosporin had antibiotic sensitivity. Therefore, 2 g/day of cephalosporin was administered for six weeks. Following this therapy, all clinical symptoms disappeared and laboratory data returned to normal levels. Tacrolimus (2 mg/day) with steroids (5 mg/day) therapy was started, and the patient had improved findings at follow-up (CRP <0.3 mg/L).

Case 2– A 62-year-old female with RA (Steinbrocker classification: functional class III, stage of disease progression 4) since 1989 was treated with non-biological disease-modifying antirheumatic drugs. Methotrexate therapy was started in 2000. However, methotrexate therapy caused interstitial pneumonitis in 2003. Therefore, we stopped methotrexate therapy, and changed the treatment with biological drug. Etanercept therapy (25 mg/week) was started in 2003. Patient underwent left THA in 2006. Etanercept therapy was discontinued for four weeks prior to THA, and restarted four weeks after THA. However, at postoperative fourth year, patient presented again with complaints of left hip pain accompanied by elevated levels of inflammation markers on laboratory examination [CRP, 8.6 mg/L (normal value; 0-0.3); white blood cells, 12,200 cell/mm³ (normal value; 3,500-9,000)]. Methicillin-resistant Staphylococcus aureus was detected in culture of joint aspiration. Open debridement was performed immediately. Vancomycin had antibiotic sensitivity. Therefore, vancomycin was administered for six weeks. Administration dose of vancomycin was adjusted by therapeutic drug monitoring (peak-to-trough concentration: 10-20 μg/mL). After the end of treatment, tacrolimus (2 mg/day) and prednisolone (5 mg/day) were introduced for the treatment of RA. Progression of RA increased in 2012, and etanercept therapy (25 mg/week) was introduced once again. After two months, patient suddenly presented with complaints of left hip pain accompanied by elevated levels of inflammation markers on laboratory examination (CRP, 3.8 mg/L; white blood cells, 10,800 cells/mm³). Methicillin-resistant Staphylococcus aureus was detected in culture of joint aspiration. Immediately, open debridement was performed, prosthesis was removed, antibiotic-impregnated, cement spacer was inserted, and vancomycin was administered for six weeks (Figure 2a). Following conclusion of the treatment, revision THA was performed which reduced progression of the infection (Figure 2b). Tacrolimus (4 mg/day) with prednisolone (5 mg/day) was introduced for the treatment of RA after THA, and the patient had improved findings at follow-up (CRP <0.3 mg/L).

DISCUSSION
A history of previous joint surgery appeared to be an associated risk factor for infection in patients receiving TNF-α blocker therapy (odds ratio= 2.07). Galloway et al. reported that exposure to TNF blocker therapy was associated with an increased risk of joint infection in patients with RA. This risk was greatest in the first year of treatment. Furthermore, joint prosthesis was

Figure 1. Short T1 inversion recovery images of magnetic resonance imaging preoperatively. (a) Axial image (b) Frontal image.
another key risk factor for infection. Therefore, the authors proposed that antibiotic guidelines should incorporate this information and consider giving specific advice for patients being actively treated with anti-TNF blocker.

Steroids are also associated with an increased risk factor for infection in RA patients treated with TNF-α blockers. Schneeweiss et al. demonstrated that the use of steroids doubled the rate of severe bacterial infections when compared with methotrexate therapy, independent of previous disease-modifying antirheumatic drug use (odds ratio = 2.1), and demonstrated a clear dose-response relationship. In our first patient, infection after THA occurred following the introduction of TNF-α blocker. The patient was concurrently treated with a steroid. These risk factors may be synergistically related to the onset of the infection.

In cases involving previous infections after total joint arthroplasty, high recurrence rates (10% at 3 years and 26% at 10 years) have been reported. The British Society of Rheumatology has indicated that previous sepsis that remains in situ, after total joint arthroplasty, is a definitive contraindication to TNF-α blocker use. Our second patient was placed on TNF-α blocker therapy following infection of the tissue surrounding the area of THA. We believe that the patient may have had a micro surgical site infection that remained asymptomatic, in which case, the sudden outbreak of infection as a reoccurrence may not have been due to the immunosuppressive effects of etanercept. Therefore, we believe that TNF-α blocker therapy should not be restarted or administered in case of previous surgical site infection after total joint arthroplasty.

To the best of our knowledge, a limited number of studies have been reported on the treatment of patients with infection after arthroplasty. Instead of biological drug therapy, we advise administration of tacrolimus therapy for patients with infection after arthroplasty. The administration of a TNF-α blocker should be carefully considered and closely followed in patients who have undergone total joint arthroplasty.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

REFERENCES